| Date | Title | Description | |
|---|---|---|---|
| 07 Nov 2024 | On P&L | The Company releases the press release related to the first nine months 2024 financial results | Download |
| 07 Nov 2024 | On P&L | The Company releases the first nine months 2024 financial results presentation | Download |
| 24 Oct 2024 | On corporate transactions | ROVI completes the strategic review of its CDMO business | Download |
| 31 Jul 2024 | On P&L | The Company releases the first half 2024 financial results presentation | Download |
| 31 Jul 2024 | On P&L | The Company releases the press release related to the first half 2024 financial results | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2023 | Annual Corporate Governance Report | ROVI releases the 2022 Annual Corporate Governance Report | Download |
| 21 Feb 2023 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors | Download |
| 16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |
| 09 Jan 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2022 | Download |
| 15 Dec 2022 | On Corporate Governance | The Company informs about changes in the Board of Directors and the creation of an Advisory Committee. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 24 Feb 2015 | Informe Anual de Gobierno Corporativo 2014 | Download | |
| 10 Feb 2015 | Otros sobre negocio y situación financiera | Download | |
| 16 Dec 2014 | I+D resultados obtenidos; licencias, patentes y marcas | Download | |
| 06 Nov 2014 | información sobre resultados | Download | |
| 06 Nov 2014 | información sobre resultados (2) | Download |